NICE Archives -

Market Access/ News/ News/ News/ Patients

Gedeon Richter gets NICE nod for uterine fibroids drug Ryeqo

Phil Taylor Gedeon Richter, HEOR, NHS, NICE, patients, relugolix, uterine fibroids, women's health 0 Comment

Around 4,500 women in the UK will be eligible for treatment with Gedeon Richter’s once-daily oral therapy Ryeqo,

Gedeon Richter gets NICE nod for uterine fibroids drug Ryeqo

https://pharmaphorum.com/news/gedeon-richter-gets-nice-nod-for-uterine-fibroids-drug-ryeqo/

Market Access/ Views & Analysis/ Views and analysis

Why companies don’t submit to NICE

Leela Barham HTA, NICE, Non-submissions 0 Comment

In March 2022, Leela Barham argued that, in light of new highs in the number of non-submissions to

Why companies don’t submit to NICE

https://pharmaphorum.com/market-access-2/why-companies-dont-submit-to-nice/

Market Access/ News/ News/ News/ Patients

NICE backs Biogen’s Vumerity for multiple sclerosis

Phil Taylor access, Biogen, multiple sclerosis, neurology, NHS, NICE, Tecfidera, Vumerity 0 Comment

Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen’s

NICE backs Biogen’s Vumerity for multiple sclerosis

https://pharmaphorum.com/news/nice-backs-biogens-vumerity-for-multiple-sclerosis/

News/ News/ Sales and Marketing

UK launches its ‘Netflix-style’ payment model for antibiotics

Phil Taylor antibiotic, antimicrobial resistance, Fetcroja, NHS, NICE, Pfizer, Shionogi, UK, value-based models, Zavicefta 0 Comment

The UK is poised to become the first country in the world to launch a new payment model

UK launches its ‘Netflix-style’ payment model for antibiotics

https://pharmaphorum.com/news/uk-launches-its-netflix-style-payment-model-for-antibiotics/

Market Access/ News/ News

NICE verdict on Trodelvy threatens unequal access to drug in UK

Phil Taylor access, England, Gilead Sciences, HEOR, NHS, NICE, Scotland, Trodelvy 0 Comment

In draft guidance, NICE has said it cannot recommend Gilead Sciences’ Trodelvy in triple-negative breast cancer (TNBC), setting

NICE verdict on Trodelvy threatens unequal access to drug in UK

https://pharmaphorum.com/news/nice-verdict-on-trodelvy-threatens-unequal-access-to-drug-in-uk/

Market Access/ News/ News

NICE reverses stance on Merck’s Bavencio for bladder cancer

Phil Taylor Bavencio, bladder cancer, Merck KGaA, NHS, NICE, Pfizer 0 Comment

Last year, NICE said that Merck KGaA/Pfizer’s Bavencio was too expensive for routine in NHS use as a

NICE reverses stance on Merck’s Bavencio for bladder cancer

https://pharmaphorum.com/news/nice-reverses-stance-on-mercks-bavencio-for-bladder-cancer/

News/ News/ Patients

NICE expands access to real-time glucose monitoring for diabetics

Phil Taylor continuous glucose monitoring, Diabetes, NHS, NICE 0 Comment

More than 250,000 people living with type 1 diabetes in the UK will be offered real-time continuous glucose

NICE expands access to real-time glucose monitoring for diabetics

https://pharmaphorum.com/news/nice-expands-access-to-real-time-glucose-monitoring-for-diabetics/

Market Access/ News/ News

NICE firms up NHS use of Vimizim for Morquio A syndrome

Phil Taylor BioMarin, HEOR, Morquio, NHS England, NICE, rare disease, Vimizim 0 Comment

In 2015, NICE said that BioMarin’s Vimizim could be used to treat patients with the ultra-rare disease Morquio

NICE firms up NHS use of Vimizim for Morquio A syndrome

https://pharmaphorum.com/news/nice-firms-up-nhs-use-of-vimizim-for-morquio-a-syndrome/

Market Access/ Views & Analysis/ Views and analysis

Time to ask companies why they don’t submit to NICE?

Leela Barham ABPI, NICE, Voluntary Scheme for Branded Medicines Pricing and Access 0 Comment

Companies can choose whether or not to submit to NICE to have their products appraised. Many do, presumably

Time to ask companies why they don’t submit to NICE?

https://pharmaphorum.com/market-access-2/time-to-ask-companies-why-they-dont-submit-to-nice/

Trending

NICE

Login